Posts

Cannabidiol as an Alternative Analgesic for Acute Dental Pain

/by

Odontogenic pain can be debilitating, and nonopioid analgesic options are limited. This randomized placebo-controlled clinical trial aimed to assess the effectiveness and safety of cannabidiol (CBD) as an analgesic for patients with emergency acute dental pain. Sixty-one patients with moderate to severe toothache were randomized into 3 groups: CBD10 (CBD 10 mg/kg), CBD20 (CBD 20 mg/kg), and placebo. We administered a single dose of respective oral solution and monitored the subjects for 3 h. The primary outcome measure was the numerical pain differences using a visual analog scale (VAS) from baseline within and among the groups. Secondary outcome measures included ordinal pain intensity differences, the onset of significant pain relief, maximum pain relief, changes in bite force within and among the groups, psychoactive effects, mood changes, and other adverse events.

Read more

Perceived Efficacy, Reduced Prescription Drug Use, and Minimal Side Effects of Cannabis in Patients with Chronic Orthopedic Pain

/by

The most important discoveries in pharmacology, such as certain classes of analgesics or chemotherapeutics, started from natural extracts which have been found to have effects in traditional medicine. Cannabis, traditionally used in Asia for the treatment of pain, nausea, spasms, sleep, depression, and low appetite, is still a good candidate for the development of new compounds. If initially all attention was directed to the endocannabinoid system, recent studies suggest that many of the clinically proven effects are based on an intrinsic chain of mechanisms that do not necessarily involve only cannabinoid receptors.

Read more

Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain

/by

Chronic non-cancer pain (CNCP) is estimated to affect 20% of the adult population. Current United States and Canadian Chronic non-cancer pain guidelines recommend careful reassessment of the risk-benefit ratio for doses greater than 90 mg morphine equivalent dose (MED), due to low evidence for improved pain efficacy at higher morphine equivalent dose and a significant increase in morbidity and mortality. There are a number of human studies demonstrating cannabis opioid synergy. This preliminary evidence suggests a potential role of cannabis as an adjunctive therapy with or without opioids to optimize pain control.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.
To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

Many cannabinoids display promising non-hallucinogenic bioactivities that are determined by the variable nature of the side chain and prenyl group defined by the enzymes involved in their synthesis.

Read more

Cannabidiol Use, Substitution for Medications, and Perceptions of Effectiveness in Women with Chronic Pelvic Pain

/by

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.
To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

Many cannabinoids display promising non-hallucinogenic bioactivities that are determined by the variable nature of the side chain and prenyl group defined by the enzymes involved in their synthesis.

Read more

Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial

/by

Aim: To determine the effect of smoked cannabis on the neuropathic pain of HIV-associated sensory neuropathy and an experimental pain model.

Read more

Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees

/by

Authors Hefei Wen, PhD; Jason M. Hockenberry, PhD Published in JAMA Internal Medicine May 2018 Abstract Importance Overprescribing of opioids is considered a major driving force behind the opioid epidemic in…

Read more

Experience of Migraine, its Severity, and Perceived Efficacy of Treatments among Cannabis Users

/by

A study from Complementary Therapies in Medicine in 2020 examines patterns of cannabis use and its associated relief among migraineurs.

Read more

Cannabis: An Emerging Treatment for Common Symptoms in Older Adults

/by

Authors: Kevin H Yang, Christopher N Kaufmann, Reva Nafsu, Ella T Lifset, Khai Nguyen, Michelle Sexton, Benjamin H Han, Arum Kim, Alison A Moore Published in Journal of the American…

Read more

Medical Cannabis Treatment for Chronic Pain: Outcomes and Prediction of Response

/by

Authors: Joshua Aviram, Dorit Pud, Tamar Gershoni, Bareket Schiff‐Keren, Miriam Ogintz, Simon Vulfsons, Tamar Yashar, Adahan Haim‐Moshe, Silviu Brill, Howard Amital, Itay Goor‐Aryeh, Dror Robinson, Leslie Green, Refael Segal, Yacov…

Read more

Delegitimizing Cannabis Because of Its Recreational Use is the Real Lie

/by

Sherry Yafai, MD encourages the need for healthcare professionals to shift their perspective on cannabis in her column for Emergency Medicine News. “Delegitimizing medications based simply on their potential for recreational use or abuse is a dangerous and uninformed approach for physicians.”

Read more

Medical marijuana certification for patients with sickle cell disease: a report of a single center experience

/by

Authors: Susanna A. Curtis, Dana Lew, Jonathan Spodick, Jeanne E. Hendrickson, Caterina P. Minniti, John D. Roberts Published in Blood Advances August 2020 Abstract More than one-third of adults with…

Read more

Frequent Cannabis Use and Cessation of Injection of Opioids, Vancouver, Canada, 2005-2018

/by

Authors: Hudson Reddon, Kora DeBeck, M Eugenia Socias, Stephanie Lake, Huiru Dong, Mohammad Karamouzian, Kanna Hayashi, Thomas Kerr, M-J Milloy Published in American Journal of Public Health August 2020 Abstract…

Read more